Lido Advisors
CRDF icon

Lido Advisors’s Cardiff Oncology CRDF Stock Holding History

Lido Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.3K Buy
15,000
+19
+0.1% +$39 ﹤0.01% 1923
2025
Q4 		$30.9K Hold
14,981
– – ﹤0.01% 1902
2025
Q3 		$30.9K Sell
14,981
-19
-0.1% -$53 ﹤0.01% 1808
2025
Q2 		$47.3K Buy
+15,000
New +$45.8K ﹤0.01% 1620

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Lido Advisors's CRDF Position: Q1 2026 in Review

Lido Advisors increased its Cardiff Oncology (CRDF) stake by 0.13% in Q1 2026, buying an estimated $39 and bringing the position to 15,000 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1923.

Lido Advisors first reported a position in CRDF in Q2 2025 and has held it in 4 quarters since. The position peaked at $47.3K in Q2 2025. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Lido Advisors held 15,000 shares of Cardiff Oncology worth $24.3K as of Q1 2026.
  • Lido Advisors bought 19 Cardiff Oncology shares in Q1 2026, an estimated $39.
  • Cardiff Oncology made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #1923 holding.
  • Lido Advisors first reported a position in Cardiff Oncology in Q2 2025 and has held it in 4 quarters since.
  • Lido Advisors's Cardiff Oncology position peaked at $47.3K in Q2 2025.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.